Stock listing

NASDAQ:CSTL Castle Biosciences, Inc. Stock

Home listing (NASDAQ) of Castle Biosciences, Inc.

Follow Castle Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CSTL

$32.86 USD -0.52 (-1.6%)

Close on Nov 20, 2026

Past year -8.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$32.57 – $33.38 USDNov 20, 2026
Volume
309,216 sharesNov 20, 2026
Market cap
$1.01B USDAt the close on Nov 20, 2026 · price × 30.82M shares outstanding
52-week range
$17.72 – $44.28 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$13.13M USDMedian day 357,666 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Castle Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CSTL · Home$32.86 USD-0.52 (-1.6%)309,216$32.76$33.38$32.57$33.38Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CSTL · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$32.86-0.52-1.6%$32.76$33.38$32.57309,216
$33.38+0.40+1.2%$32.88$34.09$32.34380,849
$32.98+0.23+0.7%$33.35$34.24$32.51339,179
$32.75-1.04-3.1%$33.42$33.65$32.46652,286
$33.79-0.71-2.1%$34.50$34.50$32.57347,752
$34.50+0.51+1.5%$33.64$34.68$32.76440,799
$33.99-0.43-1.2%$34.71$36.00$33.84335,269
$34.42+0.04+0.1%$33.96$34.58$33.52407,934
$34.38+1.86+5.7%$32.85$34.46$32.41563,375
$32.52-1.68-4.9%$34.56$35.69$31.81981,631
$34.20-1.55-4.3%$35.17$35.71$33.65701,872
$35.75+0.61+1.7%$36.03$36.43$35.07462,475
$35.14+0.20+0.6%$35.32$36.00$34.83455,612
$34.94-2.22-6.0%$37.52$37.52$34.46470,257
$37.16-1.35-3.5%$38.03$38.43$36.73334,258
$38.51+1.83+5.0%$37.57$38.73$36.09723,808
$36.68+2.17+6.3%$34.51$37.38$34.51431,159
$34.51+1.21+3.6%$33.55$34.66$33.19295,208
$33.30+0.22+0.7%$33.20$33.79$32.84235,840
$33.08-0.11-0.3%$33.41$33.62$32.69202,877
$33.19-1.18-3.4%$34.13$34.55$33.06335,419
$34.37+1.22+3.7%$33.15$34.72$32.93336,592
$33.15+0.985+3.1%$32.65$33.55$32.09272,493
$32.17+0.205+0.6%$32.44$32.74$31.67347,233
$31.96-1.84-5.4%$33.82$34.15$31.80381,900
$33.80+0.69+2.1%$33.13$34.06$32.48381,900
$33.11+0.23+0.7%$32.47$33.77$32.47243,200
$32.88+0.12+0.4%$32.79$33.35$32.23241,700
$32.76-1.66-4.8%$34.42$34.42$32.31239,000
$34.42+0.71+2.1%$33.52$34.52$33.39249,100
$33.71+0.71+2.2%$32.54$33.76$32.25373,800
$33.00-0.36-1.1%$33.15$33.72$32.77351,500
$33.36-3.29-9.0%$36.65$37.99$33.10609,100
$36.65+1.09+3.1%$35.45$36.76$35.10377,200
$35.56+0.305+0.9%$35.56$35.92$34.75167,700
$35.26-0.275-0.8%$36.10$36.99$35.17522,300
$35.53+0.65+1.9%$34.90$36.03$34.14639,600
$34.88-1.05-2.9%$35.72$36.24$34.24318,600
$35.93+0.12+0.3%$35.81$36.27$35.09228,400
$35.81+0.62+1.8%$35.19$36.12$34.44437,700
$35.19+0.31+0.9%$34.88$35.84$33.90439,200
$34.88+0.03+0.1%$34.74$34.97$33.99348,300
$34.85-0.14-0.4%$35.53$35.53$34.57431,000
$34.99-0.35-1.0%$35.68$35.68$34.48391,700
$35.34-1.44-3.9%$36.54$36.54$35.29530,200
$36.78+1.30+3.7%$35.98$36.85$34.94364,600
$35.48-0.02-0.1%$35.50$36.82$35.26559,300
$35.50+2.06+6.2%$33.64$35.69$33.64519,800
$33.44+1.11+3.4%$32.30$33.53$32.16165,400
$32.33+0.010.0%$32.77$32.94$31.71224,200
$32.32+0.010.0%$31.97$32.70$31.44237,800
$32.31-0.45-1.4%$32.43$33.03$32.00194,600
$32.76-0.15-0.5%$32.57$33.58$32.28217,000
$32.91+0.26+0.8%$32.32$33.21$31.99187,700
$32.65-0.77-2.3%$33.50$34.00$32.38268,000
$33.42-0.02-0.1%$33.36$34.73$32.69200,300
$33.44+0.41+1.2%$33.00$34.09$32.89396,200
$33.03-0.47-1.4%$33.03$33.30$32.36258,000
$33.50-0.76-2.2%$34.02$34.28$32.80372,600
$34.26+0.18+0.5%$34.01$34.89$33.98251,200
$34.08-0.92-2.6%$34.80$34.84$33.62456,300
$35.00+1.53+4.6%$33.47$35.20$33.29483,371
$33.47-0.73-2.1%$33.65$34.54$31.70357,666
$34.20+1.27+3.9%$32.85$34.70$32.14573,500
$32.93+0.61+1.9%$32.41$34.01$32.41322,900
Ticker
NASDAQ:CSTL
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Castle Biosciences, Inc. news

Castle Biosciences, Inc. on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
45 in the last 12 months · 316 in all · newest Nov 12, 2026 · oldest 2019
Calls
30 calls with a replay · 30 with a transcript · latest Nov 5, 2026
Decks
58 decks · latest November 2026

Where Castle Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CSTL · Home listing · This pageNASDAQUnited StatesUSD
Frankfurt:086FrankfurtGermanyEUR
BOATS:CSTLBOATSUnited StatesUSD
Tradegate:086TradegateGermanyEUR

Valuation

EV/sales 2.0× against a median of 4.4×: the lowest of 10 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$745.1M USD
P/E
Loss
EV/sales
2.0×
EV/EBITDA
Negative EBITDA
Price/book
2.1×
Gross margin
77.1%
Operating margin
−7.4%
Net margin
−6.1%
Debt to equity
0.0×
Beta vs S&P 500
1.00

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Castle Biosciences, Inc. · NASDAQ:CSTLUS$1.01BUS$745.1Mn/a2.0×n/a2.1×−6.1%0.0×1.00
Vcanbio Cell & Gene Engineering Corp., Ltd. Class A · SSE:600645US$1.06BUS$786.1M62.8×3.8×n/a1.9×8.2%0.0×n/a
Beijing Strong Biotechnologies Inc Class A · SZSE:300406US$1.05BUS$1.13B28.0×5.5×n/a1.9×18.2%0.3×n/a
Freenome, Inc. · NASDAQ:FRNMUS$1.04BUS$863.3M9.5×n/an/a2.2×n/a0.0×n/a
Maravai LifeSciences Holdings, Inc. · NASDAQ:MRVIUS$1.04BUS$1.11Bn/a5.2×n/a5.3×−30.8%0.8×1.56
Suzhou Novoprotein Scientific Co., Ltd. Class A · SSE:688137US$1.02BUS$909.1Mn/a38.0×n/a3.4×−60.8%0.0×n/a
Guangzhou Wondfo Biotech Co., Ltd. Class A · SZSE:300482US$1.01BUS$785.0Mn/a2.7×n/a1.2×−3.2%0.0×n/a
St Pharm Co., Ltd. · KRX:237690US$992.8MUS$866.1M17.4×3.0×11.1×2.1×19.9%0.0×n/a
Daan Gene Co., Ltd. Class A · SZSE:002030US$990.1MUS$810.9Mn/a7.0×n/a0.9×−95.7%0.0×n/a
Amoy Diagnostics Co., Ltd. Class A · SZSE:300685US$967.3MUS$801.3M18.8×4.4×n/a3.3×28.5%0.1×n/a
Novogene Co., Ltd. Class A · SSE:688315US$949.6MUS$685.6M43.1×2.0×n/a2.3×6.4%0.0×n/a
Median of the othersUS$1.01BUS$837.1M23.4×4.4×11.1×2.1×6.4%0.0×1.56

Forecasts

9 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
48.20 USD · Analysts' mean
EPS, year to Dec 2026
-0.82 · 9 analysts
Revenue, year to Dec 2026
392.4M · 9 analysts

Team and board

Officers

OfficerRole
Derek J. MaetzoldFounder, President and CEO
Frank StokesChief Financial Officer
Kristen OelschlagerChief Operating Officer
Camilla ZuckeroVice President, Investor Relations & Corporate Affairs
Alice IzzoVice President, Regulatory and Government Affairs
Chris OtteVice President, Information Technology
Clare JohnsonSenior Vice President, Clinical Research
Darshini WeeratungaVice President, Accounting and SEC Reporting
Jay BraxtonSenior Vice President, Marketing
John AbbottVice President, Finance
Keli GreenbergVice President, Human Resources
Kevin DomanSenior Vice President, Sales
Matthew GoldbergSenior Vice President, Medical
Noreen ManningVice President, Reimbursement
Rebecca Critchley-ThorneVice President, Research & Development
Reeny HedgemondVice President, Dermatology Marketing
Sherri BormanSenior Vice President, Laboratory Director
Trisha PoteetSenior Vice President, Clinical Services and Manufacturing Operations
Hillary CarusoChief of Staff
Janet KochExecutive Director, Training, Events & Marketing Operations
Jennifer SaamExecutive Director, Medical Affairs
John ChenevalExecutive Director, Business Development
Michael MaltbyExecutive Director, Managed Care
Peter ManetakisExecutive Director, Sales Operations
Toby JuvenalChief Commercial Officer

Board

DirectorRole
Daniel M. BradburyBoard Chairman
Derek J. MaetzoldFounder, President and CEO
Ellen GoldbergDirector
G. Bradley ColeDirector
Janet KochExecutive Director, Training, Events & Marketing Operations
Jennifer SaamExecutive Director, Medical Affairs
John ChenevalExecutive Director, Business Development
Kimberlee CapleDirector
Michael MaltbyExecutive Director, Managed Care
Miles HarrisonDirector
Peter ManetakisExecutive Director, Sales Operations
Rodney CottonDirector
Tiffany OlsonDirector

Events

Calls

CallWhenStatus
Castle Biosciences (NASDAQ:CSTL) Q3 2026 Earnings CallThu, Nov 05, 2026 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q2 2026 Earnings CallThu, Jul 30, 2026 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q1 2026 Earnings CallWed, May 06, 2026 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q4 2025 Earnings CallThu, Feb 26, 2026 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q3 2025 Earnings CallMon, Nov 03, 2025 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q2 2025 Earnings CallMon, Aug 04, 2025 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q1 2025 Earnings CallMon, May 05, 2025 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q4 2024 Earnings CallThu, Feb 27, 2025 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q3 2024 Earnings CallMon, Nov 04, 2024 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q2 2024 Earnings CallMon, Aug 05, 2024 · 4:30 PM ETReplay
All 30 calls
CallWhenStatus
Castle Biosciences (NASDAQ:CSTL) Q1 2024 Earnings CallThu, May 02, 2024 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q4 2023 Earnings CallWed, Feb 28, 2024 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q3 2023 Earnings CallThu, Nov 02, 2023 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q2 2023 Earnings CallWed, Aug 02, 2023 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q1 2023 Earnings CallWed, May 03, 2023 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q4 2022 Earnings CallTue, Feb 28, 2023 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q3 2022 Earnings CallWed, Nov 02, 2022 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q2 2022 Earnings CallMon, Aug 08, 2022 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q1 2022 Earnings CallMon, May 09, 2022 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q4 2021 Earnings CallMon, Feb 28, 2022 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q3 2021 Earnings CallMon, Nov 08, 2021 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q2 2021 Earnings CallMon, Aug 09, 2021 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q1 2021 Earnings CallMon, May 10, 2021 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q4 2020 Earnings CallMon, Mar 08, 2021 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q3 2020 Earnings CallMon, Nov 09, 2020 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q2 2020 Earnings CallMon, Aug 10, 2020 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q1 2020 Earnings CallMon, May 11, 2020 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q4 2019 Earnings CallTue, Mar 10, 2020 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q3 2019 Earnings CallMon, Nov 11, 2019 · 4:30 PM ETReplay
Castle Biosciences (NASDAQ:CSTL) Q2 2019 Earnings CallTue, Sep 03, 2019 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close−4.9%
Q2 2026Jul 30, 2026 · After close+4.5%
Q1 2026May 6, 2026 · After close−22.3%
Q4 2025Feb 26, 2026−4.1%
Q3 2025Nov 3, 2025 · After close+21.7%
Q2 2025Aug 4, 2025 · After close+32.8%
Q1 2025May 5, 2025 · After close−11.4%
Q4 2024Feb 26, 2025 · Before open+3.8%
Q3 2024Nov 4, 2024 · After close−7.4%
Q2 2024Aug 5, 2024 · After close+14.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · After close+6.5%
Q4 2023Feb 28, 2024 · After close−25.9%
Q3 2023Nov 2, 2023 · After close+8.0%
Q2 2023Aug 2, 2023 · After close+11.8%
Q1 2023May 3, 2023 · After close−3.9%
Q4 2022Feb 28, 2023 · After close−9.2%
Q3 2022Nov 2, 2022 · After close−2.0%
Q2 2022Aug 8, 2022 · After close+7.6%
Q1 2022May 9, 2022 · After close+5.8%
Q4 2021Feb 28, 2022 · After close+7.9%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings32 slidesNovember 2026
Q2 2026 Earnings PresentationEarnings34 slidesJul 30, 2026
Q1 2026 Earnings PresentationEarnings33 slidesMay 6, 2026
Technical Presentation (March 2026)Technical29 slidesMar 23, 2026
Q4 2025 Earnings PresentationEarnings32 slidesFeb 26, 2026
FY2025 Earnings PresentationEarnings7 slidesJanuary 2026
Fact Sheet (November 2025)Fact sheet2 slidesNov 3, 2025
Q3 2025 Earnings PresentationEarnings34 slidesNovember 2025
Fact Sheet (August 2025)Fact sheet2 slidesAug 4, 2025
Q2 2025 Earnings PresentationEarnings35 slidesAugust 2025
Show 50 decks
DeckKindSlidesDate
Q1 2025 Earnings PresentationEarnings24 slidesMay 5, 2025
Q1 2025 Earnings PresentationEarnings30 slidesMay 5, 2025
Q4 2024 Earnings PresentationEarnings26 slidesFeb 27, 2025
Q4 2024 Earnings PresentationEarnings31 slidesFeb 27, 2025
FY2024 Earnings PresentationEarnings7 slidesJanuary 2025
Q3 2024 Earnings PresentationEarnings29 slidesNov 4, 2024
Q3 2024 Earnings PresentationEarnings23 slidesNov 4, 2024
Q3 2024 Earnings PresentationEarnings29 slidesNovember 2024
Q2 2024 Earnings PresentationEarnings21 slidesAug 5, 2024
Q2 2024 Earnings PresentationEarnings29 slidesAugust 2024
Q1 2024 Earnings PresentationEarnings29 slidesMay 2, 2024
Q1 2024 Earnings PresentationEarnings24 slidesMay 2, 2024
Q1 2024 Earnings PresentationEarnings29 slidesMay 2024
Q4 2023 Earnings PresentationEarnings24 slidesFeb 28, 2024
Investor Presentation (February 2024)Investor deck28 slidesFebruary 2024
FY2023 Earnings PresentationEarnings44 slidesJan 8, 2024
Corporate Update (January 2024)Corporate update44 slidesJan 8, 2024
Q3 2023 Earnings PresentationEarnings42 slidesNov 2, 2023
Q2 2023 Earnings PresentationEarnings42 slidesAug 2, 2023
Q1 2023 Earnings PresentationEarnings19 slidesMay 3, 2023
Investor Presentation (May 2023)Investor deck47 slidesMay 2023
Investor Presentation (March 2023)Investor deck47 slidesMarch 2023
Q4 2022 Earnings PresentationEarnings20 slidesFeb 28, 2023
Q4 2022 Earnings PresentationEarnings58 slidesJan 9, 2023
Q3 2022 Earnings PresentationEarnings54 slidesNov 2, 2022
Investor Day (September 2022)Investor day110 slidesSep 20, 2022
Q2 2022 Earnings PresentationEarnings54 slidesAug 8, 2022
Q2 2022 Earnings PresentationEarnings54 slidesAug 8, 2022
Technical Presentation (June 2022)Technical5 slidesJune 2022
Q1 2022 Earnings PresentationEarnings53 slidesMay 9, 2022
FY2021 Earnings PresentationEarnings45 slidesFeb 28, 2022
Q4 2021 Earnings PresentationEarnings61 slidesJan 10, 2022
Q3 2021 Earnings PresentationEarnings54 slidesNov 8, 2021
Merger or Acquisition (October 2021)Merger or acquisition13 slidesOct 19, 2021
Wells Fargo 2021 Healthcare ConferenceConference11 slidesSep 9, 2021
Q2 2021 Earnings PresentationEarnings54 slidesAug 9, 2021
Q1 2021 Earnings PresentationEarnings53 slidesMay 10, 2021
Q4 2020 Earnings PresentationEarnings48 slidesMar 8, 2021
Investor Presentation (January 2021)Investor deck43 slidesJan 13, 2021
Technical Presentation (2021)Technical37 slides2021

This page holds 50 of 58 decks. Open Decks

Open Decks

IPO

Priced at US$16.00 a share on Jul 24, 2019.

Price
US$16.00 a share
Shares offered
4,000,000 shares of common stock
Offering size
US$64 million
Underwriters
SVB Leerink, Baird, Canaccord Genuity, BTIG · In the order on the cover
Shares delivered
On or about Jul 29, 2019

Steps

StepWhen
Draft sent to the SEC in confidenceMay 14, 2019
Filed publiclyJun 26, 2019
Amended twiceNewest Jul 19, 2019
Shares registered with an exchangeJul 15, 2019
Declared effective by the SECJul 24, 2019
Final prospectus, with the priceJul 26, 2019

Open IPO · From the cover of the final prospectus (424B4) filed Jul 26, 2019

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue344.2M332.1M219.8M137.0M94.1M62.6M51.9M22.8M13.8M
Cost of revenue71.0M60.2M45.0M32.0M15.8M9.69M7.31M5.30M4.92M
Gross profit273.2M271.9M174.8M105.0M78.3M53.0M44.6M17.5M8.83M
Research and development51.9M52.0M53.6M44.9M29.6M13.3M7.38M4.85M4.47M
Selling, general and administrative229.3M200.0M180.2M143.0M86.7M48.1M29.8M16.5M15.3M
Operating income-42.8M8.67M-68.0M-72.9M-40.1M-6.54M7.33M-3.84M-10.9M
Depreciation and amortization40.8M16.0M12.3M10.5M3.41M472.0K354.0K287.0K310.8K
EBITDA-2.04M24.7M-55.6M-62.3M-36.7M-6.07M7.68M-3.55M-10.6M
Interest expense86.0K577.0K11.0K17.0K1.00K2.63M4.57M2.27M1.65M
Income before tax-29.5M21.6M-57.4M-68.9M-40.0M-10.2M5.35M-6.36M-12.4M
Income tax-5.36M3.32M101.0K-1.77M-8.72M84.0K72.0K9.00K9.73K
Net income-24.2M18.2M-57.5M-67.1M-31.3M-10.3M5.28M-6.37M-12.4M
Earnings per share, basic-0.830.66-2.14-2.58-1.24-0.540.35-5.33-1.26
Earnings per share, diluted-0.830.62-2.14-2.58-1.24-0.54-0.21-5.33

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents116.7M119.7M98.8M122.9M329.6M409.9M98.8M4.48M1.21M
Short-term investments182.8M173.4M144.3M135.7M000
Receivables43.4M51.2M38.3M23.5M17.3M12.8M14.6M12.1M4.65M
Inventory10.3M8.13M7.94M3.98M2.02M2.22M1.24M882.0K304.6K
Current assets361.1M360.2M295.6M292.3M353.7M429.6M116.7M18.1M6.68M
Property, plant and equipment14.3M9.50M7.10M2.06M1.53M1.47M
Goodwill10.7M10.7M10.7M10.7M000
Total assets578.6M531.2M453.3M447.3M462.6M439.3M119.7M22.4M9.82M
Accounts payable18.7M6.90M10.3M4.73M2.55M2.10M1.86M1.45M1.12M
Current liabilities68.7M49.4M47.7M36.1M24.9M20.9M15.3M6.74M5.22M
Long-term debt9.64M9.74M0019.3M24.5M17.6M
Total debt10.1M10.0M013.4M8.20M026.7M24.5M18.6M
Total liabilities107.7M75.4M62.1M48.2M50.8M23.6M34.6M32.5M24.1M
Shareholders' equity470.9M455.8M391.3M399.1M411.7M415.7M85.1M-56.6M-14.3M
Shares outstanding29.7M28.5M27.4M26.6M25.4M24.8M17.1M1.92M9.78M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations64.3M64.9M-5.63M-41.7M-19.0M9.87M7.01M-12.3M-12.2M
Capital spending-36.0M-28.3M-13.6M-5.63M-3.48M-4.75M-937.0K-277.0K-494.9K
Free cash flow28.3M36.5M-19.2M-47.3M-22.5M5.11M6.08M-12.6M-12.7M
Cash from investing-60.4M-50.1M-16.2M-166.5M-66.7M-4.75M-937.0K-277.0K-494.9K
Cash from financing-6.96M6.14M-2.30M1.51M5.42M305.9M88.3M15.8M8.87M
Dividends paid-1.69M-3.12M00
Share buybacks-5.13M-1.69M-781.0K67.2M10.4M292.7K
Change in cash-2.98M20.9M-24.1M-206.7M-80.2M311.0M94.4M3.27M-3.86M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
144 · Notice of proposed saleNov 9, 2026Other filingsSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
144 · Notice of proposed saleNov 2, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 30, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 29, 2026Big-stake noticeSEC
4 · Change in ownershipOct 28, 2026Insider tradeSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
4 · Change in ownershipOct 14, 2026Insider tradeSEC
144 · Notice of proposed saleOct 13, 2026Other filingsSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
144 · Notice of proposed saleOct 5, 2026Other filingsSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
4 · Change in ownershipOct 1, 2026Insider tradeSEC
4 · Change in ownershipSep 23, 2026Insider tradeSEC
4 · Change in ownershipSep 16, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
144 · Notice of proposed saleSep 14, 2026Other filingsSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipAug 27, 2026Insider tradeSEC
4 · Change in ownershipAug 26, 2026Insider tradeSEC
144 · Notice of proposed saleAug 25, 2026Other filingsSEC
144 · Notice of proposed saleAug 24, 2026Other filingsSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
CERT · Exchange's certificate of listingAug 14, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeAug 14, 2026Other filingsSEC
4 · Change in ownershipAug 6, 2026Insider tradeSEC
4 · Change in ownershipAug 6, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
144 · Notice of proposed saleJul 31, 2026Other filingsSEC
144 · Notice of proposed saleJul 31, 2026Other filingsSEC
10-Q · Quarterly reportJul 30, 2026Quarterly reportSEC
8-K · Current reportJul 30, 2026ResultsSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
144 · Notice of proposed saleJun 16, 2026Other filingsSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
8-K · Current reportMay 29, 2026Meeting outcomeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
144 · Notice of proposed saleMay 7, 2026Other filingsSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 6, 2026ResultsSEC
4 · Change in ownershipApr 23, 2026Insider tradeSEC
4 · Change in ownershipApr 8, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 8, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 8, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 8, 2026Meeting noticeSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
144 · Notice of proposed saleMar 26, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 19, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 16, 2026Insider tradeSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
144 · Notice of proposed saleMar 12, 2026Other filingsSEC
144 · Notice of proposed saleMar 11, 2026Other filingsSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
144 · Notice of proposed saleMar 5, 2026Other filingsSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
S-8 · Registration statement for employee plansFeb 26, 2026Offer documentSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
4 · Change in ownershipJan 14, 2026Insider tradeSEC
8-K · Current reportJan 13, 2026ResultsSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
144 · Notice of proposed saleJan 5, 2026Other filingsSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
144 · Notice of proposed saleDec 17, 2025Other filingsSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
144 · Notice of proposed saleDec 11, 2025Other filingsSEC
144 · Notice of proposed saleDec 11, 2025Other filingsSEC
4 · Change in ownershipDec 8, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
144 · Notice of proposed saleNov 25, 2025Other filingsSEC
144 · Notice of proposed saleNov 24, 2025Other filingsSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
4/A · Change in ownership, amendedNov 14, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
144 · Notice of proposed saleNov 12, 2025Other filingsSEC
4 · Change in ownershipNov 6, 2025Insider tradeSEC
4 · Change in ownershipNov 4, 2025Insider tradeSEC
4/A · Change in ownership, amendedNov 4, 2025Insider tradeSEC
144 · Notice of proposed saleNov 4, 2025Other filingsSEC
S-8 · Registration statement for employee plansNov 3, 2025Offer documentSEC
10-Q · Quarterly reportNov 3, 2025Quarterly reportSEC
8-K · Current reportNov 3, 2025ResultsSEC
4 · Change in ownershipOct 23, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 9, 2025Big-stake noticeSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
144 · Notice of proposed saleOct 2, 2025Other filingsSEC
4 · Change in ownershipSep 19, 2025Insider tradeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
4 · Change in ownershipAug 29, 2025Insider tradeSEC
4 · Change in ownershipAug 29, 2025Insider tradeSEC
144 · Notice of proposed saleAug 27, 2025Other filingsSEC
144 · Notice of proposed saleAug 27, 2025Other filingsSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
144 · Notice of proposed saleAug 15, 2025Other filingsSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
144 · Notice of proposed saleAug 13, 2025Other filingsSEC
4 · Change in ownershipAug 12, 2025Insider tradeSEC
4 · Change in ownershipAug 12, 2025Insider tradeSEC
4 · Change in ownershipAug 12, 2025Insider tradeSEC
4 · Change in ownershipAug 12, 2025Insider tradeSEC
8-K · Current reportAug 8, 2025Current reportSEC
10-Q · Quarterly reportAug 4, 2025Quarterly reportSEC
8-K · Current reportAug 4, 2025ResultsSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
144 · Notice of proposed saleJun 27, 2025Other filingsSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
8-K · Current reportMay 23, 2025Meeting outcomeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 12, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 5, 2025Quarterly reportSEC
8-K · Current reportMay 5, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 23, 2025Big-stake noticeSEC
4 · Change in ownershipApr 23, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 14, 2025Big-stake noticeSEC
4 · Change in ownershipApr 10, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 9, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 9, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 9, 2025Meeting noticeSEC
144 · Notice of proposed saleApr 8, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementMar 28, 2025Meeting noticeSEC

This page holds 200 of 896 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Castle Biosciences, Inc.’s releases · as of Oct 29, 2026

Common shares
30,818,291
Fully diluted
30,818,291

Fully diluted

LineSharesAs of
Common shares30,818,291Oct 29, 2026

Share count over time

CountShares
Oct 29, 202630,818,291

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
BlackRock3.45M11.2%US$123M+162KNov 13, 2026
Rtw Investments, LP2.78M9.0%US$98.7MNo changeNov 16, 2026
Vanguard2.2M7.1%US$78M−105KNov 13, 2026
Principal1.5M4.9%US$53.3M−226KNov 2, 2026
Portolan Capital Management, LLC1.37M4.5%US$48.8M+1.04MNov 16, 2026
Acadian Asset Management LLC882K2.9%US$31.3M−36,805Nov 9, 2026
State Street805K2.6%US$28.6M−17,397Nov 12, 2026
Geode Capital794K2.6%US$28.2M−2,008Nov 6, 2026
Dimensional692K2.2%US$24.6M−98,981Nov 4, 2026
Jefferies Financial Group Inc.647K2.1%US$23MNo changeNov 5, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Summit Partners Public Asset Management, LLC635K2.1%US$22.6M−190KNov 16, 2026
Mackenzie568K1.8%US$20.2M−225KNov 2, 2026
Goldman Sachs508K1.6%US$18.1M+150KNov 16, 2026
Braidwell LP503K1.6%US$17.9MNewNov 16, 2026
Millennium496K1.6%US$17.6M+290KNov 16, 2026
Qube Research & Technologies Ltd475K1.5%US$16.9M−115KNov 13, 2026
AQR Capital Management LLC372K1.2%US$13.2M+205KNov 16, 2026
Connor, Clark & Lunn Investment Management Ltd.370K1.2%US$13.1M+37,914Nov 10, 2026
Parkman Healthcare Partners LLC368K1.2%US$13.1M+223KNov 16, 2026
Kennedy Capital Management LLC339K1.1%US$12.1M−9,108Nov 13, 2026
Panagora Asset Management Inc332K1.1%US$11.8M+30,771Nov 12, 2026
Renaissance Technologies322K1.0%US$11.5M−48,800Nov 12, 2026
Allianz302K0.98%US$10.7M−509KNov 16, 2026
Citadel301K0.98%US$10.7M+35,446Nov 16, 2026
Eventide Asset Management, LLC300K0.97%US$10.7MNewNov 13, 2026
Northern Trust281K0.91%US$9.99M−3,998Nov 16, 2026
Wasatch Advisors LP279K0.91%US$9.93M−6Oct 13, 2026
Schwab273K0.89%US$9.7M+18,404Nov 16, 2026
Kornitzer Capital Management Inc265K0.86%US$9.41M+571Nov 3, 2026
Allspring Global Investments Holdings, LLC245K0.79%US$8.7M−47,508Nov 4, 2026
Advisors Capital Management, LLC232K0.75%US$8.24M−6,284Nov 12, 2026
Trexquant Investment LP229K0.74%US$8.13M+22,807Nov 16, 2026
Bridgeway Capital Management, LLC228K0.74%US$8.1M+6,519Nov 16, 2026
Silvercrest Asset Management Group LLC227K0.74%US$8.08M−28,670Nov 16, 2026
Two Sigma215K0.70%US$7.64M+115KNov 16, 2026
Nuveen170K0.55%US$6.03M−61,901Nov 10, 2026
Hrt Financial LP158K0.51%US$5.62M+42,399Nov 13, 2026
Bank of America155K0.50%US$5.49M+55,872Nov 16, 2026
Schonfeld Strategic Advisors LLC150K0.49%US$5.34M+130KNov 16, 2026
Empowered Funds, LLC149K0.48%US$5.29M+6,519Nov 13, 2026
UBS147K0.48%US$5.23M−6,517Nov 16, 2026
Morgan Stanley146K0.47%US$5.17M−184KNov 13, 2026
Soleus Capital Management, L.P.141K0.46%US$5.01MNewNov 16, 2026
Arrowstreet Capital, Limited Partnership137K0.45%US$4.87M+44,452Nov 13, 2026
Jump Financial, LLC133K0.43%US$4.74MNewNov 13, 2026
ExodusPoint Capital Management, LP132K0.43%US$4.7MNewNov 16, 2026
BNP Paribas128K0.42%US$4.56M+58,113Nov 12, 2026
Franklin Templeton117K0.38%US$4.18M+19,179Nov 12, 2026
JPMorgan109K0.35%US$3.79M+23,761Nov 12, 2026
Fidelity108K0.35%US$3.85M+52,519Nov 10, 2026

This page holds 50 of 195 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Total Stock Market Index Fund853K2.8%US$20.3M+28,740Jun 30, 2026
iShares Russell 2000 ETF781K2.5%US$18.6M+75,482Jun 30, 2026
SmallCap Fund725K2.4%US$20.3M+16,900Jul 31, 2026
Vanguard Extended Market Index Fund343K1.1%US$8.17M+17,080Jun 30, 2026
Fidelity Small Cap Index Fund328K1.1%US$9.18M+43,391Jul 31, 2026
Strategic Advisers U.S. Total Stock Fund312K1.0%US$6.58M−352KMay 31, 2026
iShares Russell 2000 Value ETF279K0.90%US$6.65M+30,426Jun 30, 2026
Wasatch Micro Cap Fund277K0.90%US$6.6MNo changeJun 30, 2026
Vanguard Explorer Fund276K0.90%US$7.72MNo changeJul 31, 2026
Buffalo Small Cap Growth Fund240K0.78%US$5.71MNo changeJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
iShares Biotechnology ETF208K0.68%US$4.97M−7,422Jun 30, 2026
Vanguard Strategic Small-Cap Equity Fund179K0.58%US$4.28M+11,073Jun 30, 2026
Fidelity Extended Market Index Fund152K0.49%US$3.2M−850May 31, 2026
BlackRock Advantage Small Cap Core Fund152K0.49%US$3.2M−1,876May 29, 2026
Vanguard Russell 2000 Index Fund148K0.48%US$3.11M+6,915May 31, 2026
EA Bridgeway Omni Small-Cap Value ETF142K0.46%US$3.39M+10,154Jun 30, 2026
Schwab U.S. Small-Cap ETF139K0.45%US$2.92M−2,180May 31, 2026
U.S. Small Cap Portfolio135K0.44%US$3.78M+3,700Jul 31, 2026
Advisors Capital Small/Mid Cap Fund135K0.44%US$3.22MNo changeJun 30, 2026
Allspring Emerging Growth Fund134K0.44%US$3.76M+58,155Jul 31, 2026
Nuveen Quant Small Cap Equity Fund131K0.43%US$3.67M−22,764Jul 31, 2026
Allspring VT Small Cap Growth Fund131K0.43%US$3.13M+59,906Jun 30, 2026
U.S. Micro Cap Portfolio108K0.35%US$3.01M+7,918Jul 31, 2026
iShares Micro-Cap ETF100K0.32%US$2.39M+27,578Jun 30, 2026
Dimensional U.S. Small Cap ETF87,0660.28%US$2.44M−13,119Jul 31, 2026
Vanguard Health Care Index Fund86,8400.28%US$1.83M−736May 31, 2026
Goldman Sachs Small Cap Value Insights Fund82,3200.27%US$2.3M−7,659Jul 31, 2026
Omni Small-Cap Value Fund79,0000.26%US$1.88MNo changeJun 30, 2026
Schwab Small-Cap Index Fund72,7500.24%US$2.04M+9,716Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF71,7100.23%US$2.01M−11,623Jul 31, 2026
State Street(R) SPDR(R) S&P(R) Health Care Services ETF68,9660.22%US$1.64M+5,404Jun 30, 2026
SmallCap Account65,5000.21%US$1.56M+1,900Jun 30, 2026
U.S. Small Cap Value Portfolio63,2050.21%US$1.77M−3,253Jul 31, 2026
Avantis U.S. Small Cap Equity ETF58,3590.19%US$1.23M+1,436May 31, 2026
iShares U.S. Healthcare Providers ETF56,2820.18%US$1.34M+22,053Jun 30, 2026
Master Small Cap Index Series55,9570.18%US$1.33M+9,245Jun 30, 2026
Vanguard Market Neutral Fund54,5160.18%US$1.3M+9,429Jun 30, 2026
Small Company Growth Portfolio54,4210.18%US$1.3M−5,823Jun 30, 2026
Fidelity Total Market Index Fund53,8560.17%US$1.14MNo changeMay 31, 2026
Principal U.S. Small-Cap ETF49,8220.16%US$1.19M+3,540Jun 30, 2026
State Street Institutional Small-Cap Equity Fund49,2830.16%US$1.18M−1,272Jun 30, 2026
U.S. Core Equity 1 Portfolio48,4220.16%US$1.36M+11,594Jul 31, 2026
Fidelity Enhanced Small Cap Core ETF45,9000.15%US$1.09M+4,576Jun 30, 2026
Fidelity Series Total Market Index Fund44,4180.14%US$936K+1,871May 31, 2026
Fidelity Small Cap Value Index Fund41,8920.14%US$999K+6,242Jun 30, 2026
Nuveen Small Cap Blend Index Fund39,7510.13%US$1.11M+5,795Jul 31, 2026
U.S. Core Equity 2 Portfolio39,0550.13%US$1.09M−25,499Jul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF36,8330.12%US$1.03M−3,777Jul 31, 2026
Goldman Sachs Small Cap Equity Insights Fund35,0160.11%US$980K+5,751Jul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF34,6730.11%US$827K+816Jun 30, 2026

This page holds 50 of 216 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale3,904USD 32.92US$129KNov 16, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale1,642USD 32.92US$54,055Nov 16, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale1,396USD 32.92US$45,956Nov 16, 2026
Juvenal Tobin W
Officer: Chief Commercial Officer
Sale3,195USD 35.07US$112KNov 11, 2026
Juvenal Tobin W
Officer: Chief Commercial Officer
Sale2,828USD 35.04US$99,104Nov 11, 2026
Juvenal Tobin W
Officer: Chief Commercial Officer
Sale3,288USD 32.67US$107KNov 9, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale7,555USD 36.01US$272KNov 2, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale2,816USD 36.01US$101KNov 2, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale2,393USD 36.01US$86,160Nov 2, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale1,025USD 36.81US$37,734Nov 2, 2026
Show 50 trades
InsiderTradeSharesPriceValueDate
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale382USD 36.81US$14,063Nov 2, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale325USD 36.81US$11,965Nov 2, 2026
Juvenal Tobin W
Officer: Chief Commercial Officer
Sale1,237USD 35.58US$44,009Oct 28, 2026
Juvenal Tobin W
Officer: Chief Commercial Officer
Sale5,341USD 36.62US$196KOct 28, 2026
Juvenal Tobin W
Officer: Chief Commercial Officer
Sale3,288USD 33.08US$109KOct 26, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale8,580USD 31.91US$274KOct 19, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale3,198USD 31.91US$102KOct 19, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale2,718USD 31.91US$86,731Oct 19, 2026
Juvenal Tobin W
Officer: Chief Commercial Officer
Sale3,288USD 33.64US$111KOct 12, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale8,580USD 35.57US$305KOct 5, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale3,198USD 35.57US$114KOct 5, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale2,718USD 35.57US$96,668Oct 5, 2026
Oelschlager Kristen M
Officer: Chief Operating Officer
Sale2,807USD 35.75US$100KOct 1, 2026
Oelschlager Kristen M
Officer: Chief Operating Officer
Sale1,346USD 36.38US$48,967Oct 1, 2026
Juvenal Tobin W
Officer: Chief Commercial Officer
Sale1,034USD 34.20US$35,363Sep 30, 2026
Juvenal Tobin W
Officer: Chief Commercial Officer
Sale5,543USD 35.50US$197KSep 29, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale8,580USD 35.33US$303KSep 21, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale3,198USD 35.33US$113KSep 21, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale2,718USD 35.33US$96,027Sep 21, 2026
Juvenal Tobin W
Officer: Chief Commercial Officer
Sale3,294USD 35.14US$116KSep 15, 2026
Juvenal Tobin W
Officer: Chief Commercial Officer
Sale3,306USD 32.32US$107KSep 14, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale8,361USD 32.00US$268KSep 11, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale3,124USD 32.00US$99,968Sep 11, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale2,656USD 32.00US$84,992Sep 11, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale223USD 32.78US$7,310Sep 11, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale83USD 32.78US$2,721Sep 11, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale71USD 32.78US$2,327Sep 11, 2026
Oelschlager Kristen M
Officer: Chief Operating Officer
Sale3,952USD 33.36US$132KSep 1, 2026
Oelschlager Kristen M
Officer: Chief Operating Officer
Sale200USD 34.02US$6,804Sep 1, 2026
Juvenal Tobin W
Officer: Chief Commercial Officer
Sale1,730USD 32.81US$56,761Aug 31, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale11,472USD 33.14US$380KAug 28, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale2,505USD 33.14US$83,016Aug 28, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale2,129USD 33.14US$70,555Aug 28, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale257USD 33.14US$8,517Aug 28, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale956USD 33.88US$32,389Aug 28, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale209USD 33.88US$7,081Aug 28, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale177USD 33.88US$5,997Aug 28, 2026
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
Sale21USD 33.88US$711Aug 28, 2026
Juvenal Tobin W
Officer: Chief Commercial Officer
Sale9,050USD 35.04US$317KAug 25, 2026
Oelschlager Kristen M
Officer: Chief Operating Officer
Sale7,161USD 34.26US$245KAug 25, 2026

This page holds 50 of 132 trades. Open Shareholders

Big stakes

HolderStakeSharesDate
Rtw Investments, LP9.30%2.76MMar 31, 2026
BlackRock, Inc.8.20%2.34MMar 31, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Daniel Bradbury
Other companies: Vivani Medical, Inc. (Member of the Board · Since at least Mar 4, 2024); Equillium, Inc. (Chairman of the Board · Since at least Oct 11, 2018); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Intercept Pharmaceuticals Inc (Director · Jul 19, 2016 – Nov 8, 2023 · Past); BioMed Realty Trust (Director · Jan 1, 2013 – Jan 27, 2016 · Past); Corcept Therapeutics Incorporated (Director · Oct 10, 2012 – Feb 7, 2019 · Past); Geron Corporation (Director · Sep 26, 2012 – Mar 29, 2019 · Past); Illumina, Inc. (Director · Jun 8, 2006 – May 25, 2017 · Past); Paratek Pharmaceuticals Inc (Director · May 9, 2006 – Feb 13, 2008 · Past); Amylin Pharmaceuticals LLC (President & Chief Executive Of, Director · Jan 5, 2006 – Feb 22, 2012 · Past)
Board Chairman · Since at least Jul 24, 2019
David Kabakoff
Other companies: NextCure, Inc. (Director · Since at least May 8, 2019); Trius Therapeutics Inc (Director · Aug 2, 2010 – Sep 11, 2013 · Past); Avalon Pharmaceuticals Inc (Director · Oct 11, 2006 – Jun 4, 2008 · Past); InterMune Inc (Director · May 25, 2006 – Sep 29, 2014 · Past)
Director · Jul 24, 2019 – Jun 17, 2021 · Past
G. Bradley Cole
Other companies: Kiniksa Pharmaceuticals International, plc (Director · Since at least Jul 27, 2020); EXACT Sciences Corporation (General Manager - Diagnostics · Nov 11, 2019 – Feb 19, 2020 · Past); Genomic Health Inc (CFO · Oct 6, 2011 – Nov 8, 2019 · Past)
Director · Since at least Jul 24, 2019
Mara G Aspinall
Other companies: Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 27, 2021 · Past); OraSure Technologies, Inc. (Director · Jun 21, 2017 – May 13, 2025 · Past); Safeguard Scientifics, Inc. (Director · Oct 23, 2014 – May 31, 2016 · Past)
Director · Jul 24, 2019 – May 23, 2024 · Past
Bonnie H Anderson
Other companies: Bruker Corporation (Director · Since at least Sep 3, 2020); Veracyte, Inc. (Director · Oct 29, 2013 – Jun 2, 2023 · Past)
Director · Jul 24, 2019 – Jul 17, 2020 · Past
Derek Maetzold
Other companies: Encysive Pharmaceuticals Inc (V.P., Marketing & Sales · Mar 2, 2006 – Apr 1, 2008 · Past)
Founder, President and CEO · Since at least Jul 24, 2019
Frank Stokes
Other companies: Exagen Inc. (Director · Since at least Jun 17, 2021)
Chief Financial Officer · Since at least Jul 24, 2019
Frank Stokes
Other companies: Exagen Inc. (Board Member · Since at least Nov 4, 2026)
Chief Financial Officer · Since at least Aug 17, 2026
Tiffany Olson
Other companies: MiMedx Group, Inc (Director · Since at least Mar 1, 2024)
Director · Since at least May 8, 2021
Alice IzzoVice President, Regulatory and Government Affairs · Since at least Nov 5, 2026
All 41 people
PersonSeat
Bernhard E SpiessChief Business Officer · Jul 24, 2019 – Sep 2, 2021 · Past
Camilla ZuckeroVice President, Investor Relations & Corporate Affairs · Since at least Oct 28, 2026
Chris OtteVice President, Information Technology · Since at least Nov 4, 2026
Clare JohnsonSenior Vice President, Clinical Research · Since at least Nov 5, 2026
Darshini WeeratungaVice President, Accounting and SEC Reporting · Since at least Nov 5, 2026
Ellen GoldbergDirector · Since at least Jul 14, 2021
Federico A MonzonChief Medical Officer · Jul 24, 2019 – May 22, 2020 · Past
Hillary CarusoChief of Staff · Since at least Nov 5, 2026
Janet KochExecutive Director, Training, Events & Marketing Operations · Since at least Nov 5, 2026
Jay BraxtonSenior Vice President, Marketing · Since at least Nov 5, 2026
Jennifer SaamExecutive Director, Medical Affairs · Since at least Nov 5, 2026
John AbbottVice President, Finance · Since at least Nov 5, 2026
John ChenevalExecutive Director, Business Development · Since at least Nov 5, 2026
Joseph C Cook IIIDirector · Jul 24, 2019 – Mar 18, 2021 · Past
Keli GreenbergVice President, Human Resources · Since at least Nov 5, 2026
Kevin DomanSenior Vice President, Sales · Since at least Nov 5, 2026
Kimberlee CapleDirector · Since at least May 27, 2026
Kim CapleDirector · Since at least Jul 14, 2021
Kristen OelschlagerChief Operating Officer · Since at least Apr 6, 2021
Matthew GoldbergSenior Vice President, Medical · Since at least Jul 15, 2026
Michael MaltbyExecutive Director, Managed Care · Since at least Nov 5, 2026
Miles HarrisonDirector · Since at least Apr 1, 2020
Noreen ManningVice President, Reimbursement · Since at least Nov 5, 2026
Peter ManetakisExecutive Director, Sales Operations · Since at least Nov 5, 2026
Rebecca Critchley-ThorneVice President, Research & Development · Since at least Sep 9, 2026
Reeny HedgemondVice President, Dermatology Marketing · Since at least Nov 5, 2026
Rodney CottonDirector · Since at least Mar 26, 2024
Sherri BormanSenior Vice President, Laboratory Director · Since at least Nov 5, 2026
Tobin W JuvenalChief Commercial Officer · Since at least Apr 6, 2021
Toby JuvenalChief Commercial Officer · Since at least Jun 16, 2026
Trisha PoteetSenior Vice President, Clinical Services and Manufacturing Operations · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Castle Biosciences, Inc.